Project Grant R01AR082810

Award Date 9/1/24
Completion Date 6/30/29
Dollars Obligated $1.1M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Collamedix Inc. a $300,000 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to establish the feasibility of their "CollaLink" collagen-based scaffold for augmenting primary repair of anterior cruciate ligament (ACL) mid-substance tears. The project aims to demonstrate that the CollaLink scaffold, when placed around an ACL tear, can provide a...
This federal Project Grant award of $621,703, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to understand the mechanisms of tendon repair and develop treatments for tendinopathy. The award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will fund Cornell University's investigation into how changes in glycosaminoglycans (GAGs)...
This $360,580 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to develop an engineered extracellular matrix (EECM) that can promote regenerative healing in tendons. The University of Oregon will fabricate anisotropic PEG hydrogel-based EECM scaffolds and evaluate their ability to guide the alignment and matrix deposition of human...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $501,450 to The Washington University to conduct research on regulating tendon repair using stem cell-derived extracellular vesicles. The study aims to identify the specific subpopulation and active cargo molecules of extracellular vesicles that can enhance tendon healing and avoid...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $507,738 to The Trustees of the University of Pennsylvania to develop and translate a novel "tension-activated annular repair scaffold" (TARS) to address both the structural and biological requirements for repairing intervertebral disc herniations. The key objectives are to define...
This Project Grant award of $158,912 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to elucidate the role of Wnt signaling in the mechanical maturation of tendons. The research will investigate how Wnt signaling and mechanobiological cues contribute to tendon cell behavior, extracellular matrix organization, and the development of tendon's load-bearing capabilities...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, provides $488,782 to conduct research on the use of neuromuscular electrical stimulation (NMES) to address quadriceps weakness and atrophy following anterior cruciate ligament (ACL) injury and reconstruction. The overarching objective is to establish the mechanistic basis for how NMES can mitigate the...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $570,878 to the University of Rochester to conduct research on modulating myofibroblast dynamics during tendon healing. The key focus is to define the efficacy of pharmacological activation of the GPR68 receptor in regulating the tenocyte-myofibroblast transition and...
This Project Grant award, valued at $359,133.00, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports the generation of new genetic tools to enable more targeted and specific analysis of tendon and musculoskeletal tissues in mice. The goal is to develop constitutive and inducible FLP alleles that can be used in combination with existing...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA Program 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, provides $600,475 to the University of California, Davis to develop a collagen-based scaffold modified with specific integrin ligands and placental mesenchymal stem cell-derived extracellular vesicles. This innovative fetal tissue engineering approach aims to synergistically recruit and guide endogenous...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to locally deliver a small molecule Hedgehog (HH) signaling agonist to improve tendon-to-bone integration following anterior cruciate ligament (ACL) reconstruction. The $1,060,925 award will fund in vitro release studies to test the duration and bioactivity of the agonist released from innovative biomaterial scaffolds, and subsequently translate this delivery system to treat New Zealand White rabbits following ACL reconstruction. The research objectives are to stimulate progenitor cell proliferation and differentiation into fibrochondrocytes to enhance zonal attachment formation and improve integration strength at the tendon-to-bone interface. Additionally, the study will assess the long-term effects of agonist release on joint health. The award was granted to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, and has an ultimate completion date of June 30, 2029.

Generated 8/5/25, 6:00 AM